Merck & Co., Inc. (NYSE:MRK) Stock Has Consensus Price Target of $146.36

Merck & Co., Inc. (NYSE:MRK) has received an average recommendation of “Moderate Buy” from the twenty-seven brokerages that are covering the firm, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $151.32.

Several equities analysts have recently commented on the company. Bank of America upped their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Morgan Stanley decreased their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Wednesday. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $142.00 to $150.00 in a report on Thursday, August 20th. TD Cowen boosted their target price on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a research report on Wednesday, September 23rd. Finally, Sanford C. Bernstein raised their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research report on Tuesday, August 4th.

Insider Activity at Merck & Co., Inc.

In related news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. This trade represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRK. BlackRock Inc. raised its stake in Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp grew its stake in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after buying an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Bank of America Corp DE increased its holdings in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after buying an additional 2,919,780 shares during the period. Finally, Invesco Ltd. increased its holdings in Merck & Co., Inc. by 3.5% in the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock valued at $2,162,691,000 after buying an additional 701,249 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View
• Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target
• Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option?
• Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $142.45 on Tuesday. The firm has a 50-day moving average of $143.59 and a 200-day moving average of $128.16. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market cap of $351.45 billion, a PE ratio of 113.96, a P/E/G ratio of 6.42 and a beta of 0.21. Merck & Co., Inc. has a 52-week low of $82.01 and a 52-week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. Merck & Co., Inc.’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 2.67 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.